hers hims news - Search News

Hims & Hers Health stock tanks

Fast Company on MSN · 1d

Hims & Hers Health stock tanks after FDA says competitor Eli Lilly’s weight-loss drug shortage is over

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 medications. Shares of Hims & Hers Health fell almost 10% today following an announcement from the U.

YAHOO!Finance · 1d

Hims & Hers stock falls after Eli Lilly's weight-loss drug dropped from shortage list

Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed them from its shortage list — signaling the pharmaceutical giant's ability to now meet market demand.

MarketWatch · 1d

Hims & Hers Health Shares Fall After FDA Removes Eli Lilly Obesity Drugs From Shortage List

Shares in Hims & Hers Health fell after the U.S. Food and Drug Administration said Eli Lilly's obesity and diabetes drugs are no longer in shortage. Shares were down 7% in premarket trading to $17.64.

Nvidia, Levi Strauss & Co & Hims & Hers Health Inc

CNBC on MSN · 1d

3-Stock Lunch: Nvidia, Levi Strauss & Co & Hims & Hers Health Inc

Quint Tatro, Joule FInancial president, joins 'Power Lunch' to discuss stock plays for three stocks.

Why Did Hims & Hers Health Inc (HIMS) Stock Surge 9.02% Last Week?

On Friday, Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $17.77 which represents a slight increase of $0.06 or 0.34% from the prior close of $17.71. The stock opened at $17.

Barron's on MSN · 1d

These Stocks Are Moving the Most Today: EVgo, Levi Strauss, Humana, Hims & Hers, Nvidia, Stellantis, and More

EVgo stock surges after the company receives a $1 billion Energy Department loan commitment, Levi Strauss tumbles after cutting its fiscal-year revenue outlook, and Humana extends losses.

1don MSN

For Hims & Hers Stock, GLP-1 Giveth and GLP-1 Taketh Away

Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.

1d

Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward

Anticipating a 35% CAGR in 2025, Hims & Hers is poised for substantial growth. Read why I maintain my strong buy rating on ...

1d

Is the soaring Hims & Hers stock a good investment?

Hims & Hers (NASDAQ: HIMS) stock has done well since the company went public a few years ago. It has soared by over 193% in ...

16d

Hims & Hers to Offer Weight Loss Medication for Workers in Specific Professions

There is soaring demand for weight-loss drugs in the GLP-1 class, and the company will now sell it to certain professions for ...

9d

Hims & Hers: The Gift That Keeps On Giving

Hims & Hers stock is currently in the middle of a deep drawdown. Read why I maintain my strong buy rating on HIMS stock.

17d

1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)

At the time, Teladoc Health was hailed as the ultimate telemedicine darling; its stock price skyrocketed to nearly $300 per ...

2d

Weight Loss Solutions for Front-Line Heroes: Hims & Hers Tackles Barriers

Hims & Hers is making GLP-1 weight loss medications more accessible with a 50% discount for front-line heroes. Mihir Gandhi ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results